Roche Holding AG
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-24.8% vs price
Base Case (Median)
33.1% vs price
Bull Case (75th pct.)
54.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $94.74 | 85.3% | High (40%) |
| PE Comparable | $68.05 | 33.1% | Medium (25%) |
| Growth Trajectory DCF | $78.44 | 53.4% | Medium (20%) |
| Graham Number | $19.08 | -62.7% | Medium (40%) |
| EV/EBITDA | $33.80 | -33.9% | Medium (20%) |
| EV/FCF | $79.16 | 54.8% | Medium (20%) |
| Earnings Power Value | $43.15 | -15.6% | Medium (50%) |
Based on 7 out of 8 methods, RHHBY appears fairly valued at the current price of $51.13. The base case fair value of $68.05 implies 33.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.